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Background: It has been reported that GLP-1 agonist exenatide (exendin-4) decreases blood pressure. The
dose-dependent vasodilator effect of exendin-4 has previously been demonstrated, although the precise
mechanism is not thoroughly described. Here we have aimed to provide in vitro evidence for the hypothesis that
exenatide may decrease central (aortic) blood pressure involving three gasotransmitters, namely nitric oxide (NO)
carbon monoxide (CO), and hydrogen sulphide (H2S).
Methods: We determined the vasoactive effect of exenatide on isolated thoracic aortic rings of adult rats. Two
millimetre-long vessel segments were placed in a wire myograph and preincubated with inhibitors of the enzymes
producing the three gasotransmitters, with inhibitors of reactive oxygen species formation, prostaglandin synthesis,
inhibitors of protein kinases, potassium channels or with an inhibitor of the Na+/Ca2+-exchanger.
Results: Exenatide caused dose-dependent relaxation of rat thoracic aorta, which was evoked via the GLP-1 receptor
and was mediated mainly by H2S but also by NO and CO. Prostaglandins and superoxide free radical also play a part in
the relaxation. Inhibition of soluble guanylyl cyclase significantly diminished vasorelaxation. We found that
ATP-sensitive-, voltage-gated- and calcium-activated large-conductance potassium channels are also involved in the
vasodilation, but that seemingly the inhibition of the KCNQ-type voltage-gated potassium channels resulted in the
most remarkable decrease in the rate of vasorelaxation. Inhibition of the Na+/Ca2+-exchanger abolished most of the
vasodilation.
Conclusions: Exenatide induces vasodilation in rat thoracic aorta with the contribution of all three gasotransmitters.
We provide in vitro evidence for the potential ability of exenatide to lower central (aortic) blood pressure, which could
have relevant clinical importance.
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Exenatide (exendin-4), a glucagon-like-peptide (GLP-1)
receptor agonist, binds to the GLP-1 receptor (GLP-1R),
which is present as well as elsewhere on endothelial and
vascular smooth muscle cells [1,2]. GLP-1R is highly
expressed in rat thoracic aorta [3]. Several studies have
demonstrated that GLP-1 causes relaxation of arteries in
a concentration-dependent manner, however, findings* Correspondence: istvan.wittmann@aok.pte.hu
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unless otherwise stated.on the putative mechanism of the vasodilator effect of
GLP-1 appear controversial [3-7]. Both endogenous
GLP-1 and exendin-4 induced vasorelaxation of the rat
thoracic aorta via the involvement of ATP-sensitive po-
tassium channels (KATP) and cyclic-adenosine monopho-
sphate (cAMP) [3]. In rat femoral artery, GLP-1 caused
endothelium-independent, dose-dependent relaxation
[4], while in pulmonary arteries the vasodilation due to
GLP-1 was described as endothelium-dependent [5,6].
GLP-1 was also described as elevating plasma nitric
oxide (NO) levels, hence being a potent endothelial
vasodilator [7]. Besides the activation of KATP channels,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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voltage-gated potassium channels (Kv) [3,8,9].
NO, carbon monoxide (CO), and hydrogen sulphide
(H2S) are gaseous signalling molecules, mediating vaso-
dilatory effects in the arterial tree [10]. They are all known
to act via the formation of cyclic nucleotides (cAMP/
cGMP) and activation of intracellular protein kinases
(PKA/PKG) and to cause vasodilation via modulating po-
tassium channels [10]. The vasorelaxation in response to
H2S often evolves by the activation of KATP channels and
the KCNQ-type voltage gated potassium channels [10,11].
In mice models of hypertension KCNQ channel openers
are proven to reduce arterial blood pressure [12]. Both CO
and superoxide (O2
–•) are known activators of Kv channels
[13]. The vasodilator effect of CO partially lies in the acti-
vation of these channels; moreover, the activation of PKG
or the activation of PKA by NO results in the opening of
these channels [10,13].
The aim of this study was to determine the mediators
and second messengers involved in the vasodilator effect
of exenatide, therefore we studied the effect of exenatide
on gasotransmitters and ion channels in rat thoracic aorta.
Materials and methods
Animals
We performed our experiments with the permission of
the Hungarian Local Animal Experiment Committee in
accordance with the ‘Principles of laboratory animal
care’ (NIH publication no. 85–23, revised 1985). Adult,
10–12 week old (280–340 g) male CFY Sprague-Dawly
rats were kept on a standard chow. Animals were origin-
ally purchased from Charles River Laboratories GmbH
(Sulzfeld, Germany). On the day of the experiment, after
anesthetization with ether, rats were killed by decapita-
tion using guillotine.
Vasoreactivity experiments
The thoracic aorta was gently excised from rats and was
placed in oxygenated (95% O2/5% CO2), ice-cold Krebs
solution (119 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4,
25 mM NaHCO3, 1.2 mM Mg2SO4, 11.1 mM glucose,
1.6 mM CaCl2*2H2O, pH 7.4). As described earlier, the
perivascular fat and connective tissue were gently re-
moved [12,14], and 2 mm long segments of the vessel
were mounted on two stainless steel wires (40 μm in
diameter), and placed in 5 ml organ baths of a wire myo-
graph (Danish Multimyograph Model 610 M, DMT- USA
Inc., Atlanta, GA, USA). Vessel rings were kept in Krebs
solution at 37 ºC, pH 7.4 and were continuously oxygen-
ated with a gas containing 95% O2 and 5% CO2. The rings
were placed under a tension of 1 g [3]. Isometric tension
was continuously recorded. After a 30 minutes resting
period, vessel rings were preconstricted with 100 nM epi-
nephrine as described earlier, which in our previouslyperformed experiments had shown 60% contraction force of
the 60 mM KCl contraction [15]. After all vessel segments
had reached a stable contraction plateau, increasing doses of
exenatide (Byetta® injection, Bristol-Myers Squibb–
AstraZeneca, Budapest, Hungary) were administered to
the organ baths, and relaxant responses were assessed.
The dose of exenatide that was applied to relax the
aorta correlated with the dose of epinephrine we used
to preconstrict the vessels. Plasma epinephrine level is
approximately 30 pM at rest, while in our experiments
we used 100 nM, which is a 3000 times higher concen-
tration [16]. The plasma exenatide level was found to
be 70 pM, while in our experiments we used a 4500
times higher concentration [17].
In order to identify the extracellular and intracellular me-
diators of the vasodilator effect of exenatide we performed
a series of experiments. Prior to contracting the vessels
with epinephrine we preincubated the vessels (n = 5 of
each experiment) with different materials. To deter-
mine whether the vasodilation due to exenatide evoked
via the GLP-1R, we preincubated vessels with GLP-1R
antagonist exendin(9–39) (32 μM, 30 min). Because the
affinity of exendin(9–39) to bind GLP-1R is smaller
than that of exenatide, we applied a ten times higher
concentration of the receptor antagonist than the high-
est dose of exenatide [18]. In one set of experiments we
mechanically removed the endothelium of the vessels
by gently rubbing a hair through it. The effect of de-
nudation was verified by the loss of response to 3 μM
acetylcholine. We incubated one group of vessels with
the eNOS inhibitor L-NAME (300 μM, 30 min). Other
vessels were incubated with the potent heme oxygenase
inhibitor Tin-protoporphyrin IX dichloride (10 μM,
30 min), others with DL-Propargylglycine, inhibitor of
cystathionine-γ-lyase (10 mmol/l, 30 min), or with the
relatively selective COX-1 inhibitor indomethacin (3 μM,
30 min). We tested the effects of free radical scavengers
superoxide dismutase (SOD; 200 U/ml, 30 min) and cata-
lase (1000 U/ml,30 min). H89 hydrochloride (5 μM,
30 min) was used to block protein kinase A (PKA), and
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one (ODQ, 3 μM,
30 min) was used to inhibit the effect of soluble guanylyl
cyclase (sGC). To block the large-conductance calcium-
activated potassium channels (BKCa channels) some vessels
were incubated with tetraethylammonium (TEA, 2 mM)
for 30 minutes [13]. To block the ATP-sensitive potassium
(KATP) channels we used glibenclamide (10 μM, 30 min)
[13]. KCNQ-type voltage-dependent potassium channels
were blocked by incubation with XE991 (30 μM, 15 min)
[14]. The Na+/Ca2+-exchanger was blocked by incubation
with its specific inhibitor SEA0400 (4 μM, 30 min) [19].
To exclude the effect of spontaneous vessel relaxation we
performed untreated time-control experiments; however,
the spontaneous vessel relaxation of untreated aortic rings
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tors on the permanence of the epinephrine-induced plateau,
we performed a row of control experiments, and found that
most of the chemicals had a slight vasodilatory effect which
could not have a significant influence on the results.
Chemicals were purchased from Sigma-Aldrich, St. Louis,
MO, USA, except for Tin-protoporphyrin IX dichloride,
which was purchased from Santa Cruz Biotechnology
(Dallas, Texas, USA); XE991 was purchased from Ascent
Scientific Ltd. (Avonmouth, Bristol, UK), and epinephrine
was purchased from Richter-Gedeon Hungary (Budapest,
Hungary). SEA0400 was synthesized in the Institute of
Pharmaceutical Chemistry, University of Szeged, Szeged,
Hungary by Professor Ferenc Fülöp.
Myodaq 2.01 M610+ software was used for data acqui-
sition and display. We expressed the rate of relaxation
caused by exenatide as the percentage of the contraction
evoked by epinephrine.Statistical analysis
Statistical analysis was performed by using SPSS Version
19.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism
6.0 (GraphPad Software Inc., La Jolla, CA, USA). Statis-
tical significance was calculated using Student’s t-test or
ANOVA with Bonferroni post hoc test as appropriate.
Values are shown as mean ± SE. A value of P less than
0.05 was considered to be significant.Results
Exenatide relaxes rat thoracic aorta in a dose-dependent
manner
After precontracting the vessels with epinephrine, time-
control experiments showed that spontaneous vessel relax-
ation was not significant (Figure 1A). Following the
epinephrine-induced contraction, in an other set of experi-
ments we administered increasing doses of exenatide toFigure 1 Effect of exenatide on the vasoactivity of rat thoracic aorta. Or
contracted aortic segment (A). Dose-dependent vasodilatory effect of exenat
310, 788, 1980, 3170 nanomoles of exenatide were used to relax the vessels (the organ baths to assess the vasoactive effect of this GLP-
1R agonist. We found a dose-dependent relaxation of the
rat thoracic aorta due to exenatide (Figure 1B).
Role of GLP-1 receptor
In our experiments exenatide induced vasodilation in a
GLP-1R dependent manner, since preincubation with
the specfic GLP-1R antagonist exendin(9–39) almost en-
tirely blocked the vasodilation when the maximal dose
of exenatide was applied, and totaly inhibited relaxation
when smaller concentrations of the GLP-1 agonist were
administered to the chambers (Figure 2A).
Effects of exenatide after endothelial denudation
When the endothelium of the thoracic aorta was mech-
anically removed, the relaxation due to exenatide was
significantly decreased (Figure 2B).Effect of exenatide on the production of gasotransmitters
Incubation of vessels with the eNOS inhibitor L-NAME
led to a mild but significant decrease in the relaxation of
the rat thoracic aorta (Figure 3A). To determine further
mediators of the vasodilator effect of exenatide, we ex-
amined the role of CO and H2S. When we preincubated
vessels with Tin-protoporphyrin, a potent heme oxy-
genase inhibitor, the vasorelaxation to exenatide was
significantly reduced (Figure 3B). The inhibition of NO-
synthesis and the inhibiton CO-production only partially
decreased the rate of vasodilation: we therefore wished to
prove that the third gasotransmitter, H2S also plays a part
in the vasoactive effect of exenatide. The inhibition of
cystathionine-γ-lyase by preincubating vessels with PPG
resulted in a significant decrease in the rate of relaxation
(Figure 3C). Comparing the effects of these three gaso-
transmitters leading to vasodilation in response to exe-
natide, H2S seemed to have the most remarkable effect.iginal records of myography experiments. Time-control of an epinephrine
ide on rat thoracic aorta following epinephrine contraction. 23.9, 71.7,
B) (n = 5 of each experiment).
Figure 2 Role of GLP-1 receptor and endothelial denudation in the vasodilatation due to exenatide. Exenatide concentration-relaxation
curves of vessels treated with exenatide only (▲) and vessels preicubated with GLP-1R anatagonist exendin(9–39) (■) (A). Vasodilation evoked by
exenatide in endothelium-intact and endothelium-denuded vessels (B). 23.9, 71.7, 310, 788, 1980, 3170 nanomoles of exenatide were used to
relax the vessels (n = 5 of each experiment), *P < 0.01 compared to exenatide only (at respective concentration of exenatide).
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Incubation of vessels with the COX inhibitor indometh-
acin for 30 minutes significantly decreased vasodilation
to exenatide (Figure 3D).
Free radicals play a part in the vasoactive effect of exenatide
To determine the role of ROS in the vasorelaxation
caused by exenatide, we preincubated vessels with super-
oxide dismutase or with catalase. The rate of relaxation
was significantly decreased in both experiments; how-
ever, SOD proved to be a more potent inhibitor of vaso-
dilation to exenatide (Figure 4).
Effects of inhibiting the cAMP-dependent protein kinase
A and cGMP-dependent protein kinase G
In order to determine the second messenger of the dilata-
tion caused by exenatide, we incubated vessels with H89,Figure 3 Role of gasotransmitters and prostaglandins in the vasodila
-Nitro-L-arginine methyl ester hydrochloride (L-NAME) (A). Inhibition of CO
Tin-protoporphyrin IX dichloride (B). Blocking H2S production by inhibiting
(C). Inhibition of prostaglandin production with 3 μM indomethacin (D). 23
relax the vessels (n = 5 of each experiment), *P < 0.01 compared to the relaxaan inhibitor of PKA. This caused only a mild decrease in
the vasorelaxation at a low concentration (Figure 5A). In
turn, inhibition of soluble guanylyl cyclase by ODQ sig-
nificantly inhibited the vasorelaxation at higher concentra-
tions as well (Figure 5B).Role of potassium channels in the vasodilator effect of
exenatide
Preincubating vessels with three different potassium
channel blockers before adding increasing concentra-
tions of exenatide to the myograph chambers resulted in
a signifcant decrease in the relaxation of all cases. Incu-
bating one group of vessels with TEA, an inhibitor of
the BKCa channels, demonstrated inhibition of vasodila-
tion (Figure 6A). Relaxation was also inhibited by a
blockade of the KATP channels by preincubation withtory effect of exenatide. Inhibition of eNOS with 300 μM Nω
production by blocking heme oxygenase enzyme with 10 μM
cystathionine-γ-lyase with 10 mM DL-Propargylglycine (PPG)
.9, 71.7, 310, 788, 1980, 3170 nanomoles of exenatide were used to
tion caused by exenatide only (at respective concentration of exenatide).
Figure 4 Effect of free radicals on the vasodilation due to exenatide. Concentration-relaxation curve of exenatide with/without the addition
of 200 U/ml of the free radical scavanger superoxide dismutase (SOD) (A). Concentration-relaxation curve analyzing the possible role of hydrogen
peroxide by blocking its formation with 1000 U/ml catalase (B). 23.9, 71.7, 310, 788, 1980, 3170 nanomoles of exenatide were used to relax the
vessels (n = 5 of each experiment), *P < 0.01 compared to the relaxation caused by exenatide only (at respective concentration of exenatide).
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cubated with XE991, a KCNQ (a type of Kv channels)
channel inhibitor, most of the vasodilation was abolished
(Figure 6C). However, there was a less pronounced de-
crease of vasodilation with the inhibition of BKCa and
KATP channels compared to the inhibition of Kv
channels.
Effects of inhibiting the Na+/Ca2+-exchanger with
SEA0400
We found that SEA0400, an inhibitor of the Na+/Ca2+-ex-
changer markedly inhibited vasorelaxation. Preincubation
of vessels with SEA0400 almost completely abolished the
whole of the vasodilation caused by exenatide (Figure 6D).
Discussion
In our study we demonstrated that exenatide causes vaso-
relaxation of isolated rat thoracic aorta in a dose-
dependent manner. Based on our findings, the hypothetical
mechanism of the vasorelaxation caused by exenatide is as
follows: exenatide binds to GLP-1R and activates both
endothelial and vascular smooth muscle cells, leading to
the production of H2S, NO, CO, O2
–•, H2O2 and prosta-
glandins. Formation of these relaxing factors contributes to
the activation of potassium channels either directly or by
activating PKG or - to a lesser extent - PKA. SubsequentFigure 5 Concentration-relaxation curves showing the possible effector
dependent protein kinase A (PKA) with 5 μM H89 hydrochloride (A). Inhibiton
310, 788, 1980, 3170 nanomoles of exenatide were used to relax the vessels (n
by exenatide only (at respective concentration of exenatide)activativation of the Na+/Ca2+-exchanger resulting in cal-
cium efflux leads to smooth muscle relaxation, and thus
vasorelaxation (Figure 7).
While GLP-1 amides were found to have GLP-1R-
dependent and –independent vasodilatory effects, in our
experiments exenatide caused relaxation of the rat thor-
acic aorta in a GLP-1R dependent manner [1]. This find-
ing is congruent with a study that demonstrated that
GLP-1R agonists reduce systolic blood pressure via the
GLP-1R, however the same study reported that the antihy-
pertensive effect was NO-independent and that vasodila-
ton is evoked by the increased secretion of the atrial
natriuretic peptide (ANP) due to GLP-1R activation [32].
Non-PKA GLP-1R-dependent effects have been shown in
the regulation of eNOS expression in aortic endothelial
cells in an ApoE−/− mouse model, suggesting the role of
GLP-1 agonists in the inhibition of endothelial cell dys-
function [33].
Previously exendin-4 was found to relax isolated rat
thoracic aorta involving KATP and cAMP, although the re-
laxation caused by endogenous GLP-1 amides was greater
than those caused by the synthetic peptides [3]. The same
study stated that the relaxation caused by physiological
isoform GLP-1(7–36)amide was not altered by endothelial
denudation or incubation either with L-NAME, indometh-
acin or catalase [3]. Conversely, we found that thesemolecules of the exenatide induced vasodilation. Blocking cAMP-
of soluble guanylyl cyclase with 3 μM 1H- (1,2,4) (ODQ) (B). 23.9, 71.7,
= 5 of each experiment), *P < 0.01 compared to the relaxation caused
Figure 6 Role of potassium channels and the Na+/Ca2+-exchanger in the vasodilator effect of exenatide. Blockade of large-conductance
calcium-activated potassium channels with 2 mM tetraethylammonium (TEA) (A). Inhibition of ATP-sensitive potassium channels with 10 μM
glibenclamide (B). KCNQ-type Kv channels blocked by 30 μM XE991 (C). Selective inhibition of the Na
+/Ca2+-exchanger with 4 μM SEA0400
(D). 23.9, 71.7, 310, 788, 1980, 3170 nanomoles of exenatide were used to relax the vessels (n = 5 of each experiment), *P < 0.01 compared to the
relaxation caused by exenatide only (at respective concentration of exenatide).
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caused by exenatide, indicating a role of the endothelium
in vasorelaxation due to exanatide but not the endogenous
GLP-1-amides [3].
Endogenous GLP-1 has been shown to cause endothe
lium-dependent vasorelaxation via NO; however, data
regarding GLP-1-induced endothelium-independent va-
sorelaxation have also been published [4-7]. NO, formed
by the endothelial nitric oxide synthase (eNOS) enzyme,
acts via activating soluble guanylyl cyclase (sGC) leading
to an increased production of cyclic-guanosine monopho-
sphate (cGMP) which activates the cGMP-dependent pro-
tein kinase (PKG) [10]. Alternatively, NO was shown to
increase cAMP levels in cardiac myocytes by activating
adenylyl cyclase in a cGMP-independent manner, result-
ing in the activation of the cAMP-dependent protein kin-
ase (PKA) [20]. On the other hand, in vascular smooth
muscle cells NO may have vasodilatory effect via the dir-
ect activation of the large-conductance calcium activated
potassium channels (BKCa channels) [13]. In our experi-
ments we demonstrated that NO is only partially respon-
sible for the vasodilator effect of exenatide in rat thoracic
aorta. This finding is in contrast with a previous study
where endothelial denudation and preincubation with L-
NAME had no significant effect on the vasodilation
caused by endogenous GLP-1 in rat thoracic aorta [3].
Although GLP-1 was shown to cause significant vasore-
laxation of rat saphenous artery and recruitment of mucle
microvasculature via the NO/PKA pathway, we found that
these mechanism are only partially responsible for the
vasodilation evoked by exenatide in the thoracic aorta ofrats [34]. The possible explanation for the discrepancies
between former studies and ours may be that we studied
the effects of the GLP-1 agonist exenatide while in previ-
ous studies the endogenous, physiological isoform GLP-1
(7–36) amide was used [3-6].
Although previously only NO was found to be involved
in the GLP-1-induced vasodilatation [4-7] among the
three gasotransmitters, we found that CO and H2S also
contribute. CO, an important regulator of vascular tone, is
a vasodilator gaseous molecule formed from heme by
heme oxygenase (HO) in vascular smooth muscle cells
[10]. Similar to NOS, HO has three isoforms, of which
HO-2 is constitutively expressed in endothelial cells and
vascular smooth muscle cells [10,21]. CO acts through the
activation of sGC, but also increases the calcium sensitiv-
ity of BKCa channels, which in turn leads to smooth
muscle hyperpolarization [22]. CO may also cause vaso-
dilation through the activation of voltage-dependent po-
tassium channels (Kv) [22].
We also demonstrated the involvement of the third gaso-
transmitter, H2S, in mediating the vasodilatory effect of exe-
natide. H2S is formed in endothelial cells and vascular
smooth muscle cells from homocystein, cysthationine or L-
cysteine by cystathionine-γ-lyase, cystathionine-β-synthase
and 3-mercaptopyruvate-sulfurtransferase (3MST) [23]. H2S
has been shown to act via the sGC-cGMP-PKG pathway
and also via to the activation of ATP-sensitive and KCNQ-
type voltage-gated potassium channels (KATP), causing hy-
perpolarization of smooth muscle cells [11,24,35]. H2S was
also shown to activate adenylyl cyclase, which generates
cAMP, thereby activates PKA leading to vasodilation [25].
Figure 7 Hypothetical mechanism of the exenatide induced
vasodilation according to our data and according to previous
examinations [3-7,10-14,19-31]. HO: heme oxygenase, eNOS
endothelial nitric oxide synthase, CSE: cystathionine-γ-lyase, COX:
cyclooxygenase, PG: prostaglandin, H2S: hydrogen sulphide NO: nitric
oxide, CO: carbon monoxide, O2
–•:superoxide anion, PKA: cAMP-
dependent protein kinase, PKG: cGMP-dependent protein kinase,
BKCa: large-conductance calcium activated potassium channel, KCNQ:
a type of voltage-gated potassium channel, KATP: ATP-sensitive
potassium channel.
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that prostaglandins and reactive oxygen species are also in-
volved in the vasorelaxation due to exenatide, although to a
variable extent. In certain arteries reactive oxygen species
(ROS) play a role in the mediation of vasodilation [36]. They
were also found to relax both pulmonary and mesenteric ar-
teries [37,38]. In superoxide-dismutase (SOD) knockout mice
eNOS-dependent endothelium-mediated vasorelaxation is
impaired, suggesting the role of superoxide anion (O2
–•) in
vasodilation [39].
Potassium channels are often targets of gaseous media-
tors, resulting in vasodilation [13]. KATP and Kv channels
are inhibited by GLP-1 in β-cells [8,9], but we found that
both channels are activated by exenatide in the vascula-
ture, leading to vasodilation of the isolated rat thoracicaorta. Moreover, in our experiments we demonstrated that
the blockade of KCNQ type voltage-gated potassium
channels abolished the vasodilation caused by exenatide,
which has not been observed before. GLP-1 was formerly
shown to cause vasodilation of rat thoracic aorta via the
activation of KATP channels [3]. In a human ischaemia-
reperfusion injury model subcutaneously administered
exenatide was found to be protective against endothelial-
dysfunction via the opening of KATP channels [40]. We
found that inhibition of KATP channels significantly de-
creased the exenatide evoked vasodilation, altough it did
not appear to be as impressive as the inhibition of KCNQ
type Kv channels.
Activation of BKCa channels by exenatide has not been
described previously. Nevertheless, we found that the
blockade of these channels with TEA also inhibited vaso-
relaxation, but that this occurred only in higher concen-
tration. It is well-established that NO and CO exert
vasodilatory effects by activating BKCa channels [10,13].
We demonstrated that the inhibition of the sodium-
calcium exchanger (Na+/Ca2+-exchanger or NCX) mark-
edly inhibited vasodilation evoked by exenatide, which has
not been shown before. NCX is a transmembrane protein
located in almost all cell types [26]. The key function of
NCX is to deliver calcium with a simultaneous entry of so-
dium into the cell upon repolarization, whereas when the
cell membrane is depolarized, its activity is reversed and it
induces calcium influx [26,27]. NO was observed to
decrease the vasoconstriction mediated by the NCX in rat
aorta [28].
In this study we provide in vitro evidence for the possibil-
ity that GLP-1 receptor agonist exenatide decreases central
(aortic) blood pressure. Central blood pressure indicates
the load affecting the left ventricle, the coronary and
cerebral vessels, and it correlates closely with the risk of
cardiovascular (CV) events, thereby demonstrating the
value of our findings in the clinical context [41]. The CAFE
study established that central aortic pressure is a strong
predictor of clinical outcomes [42]. There is also in vivo evi-
dence that exenatide reduces both systolic and diastolic
blood pressure [43]. Moreover, GLP-1 receptor agonists are
associated with outstanding improvements of other CV risk
factors such as body weight and lipid profiles, while they
have only a small effect on heart rate and QTc. [44]. Exena-
tide was found to be more beneficial than biguanides,
dipeptidyl peptidase-4 inhibitors, thiazolidindiones, or basal
insulin, in reaching the therapeutic goals recommended by
the American Diabetes Association (ADA) in the treatment
of type 2 diabetes, which is also promising in the reduction
of cardivascular risk [45]. Treatment with exenatide has
shown to have similarly beneficial effects on microvascular
endothelial function, oxidative stress, vascular activation
and markers of inflammation as metformin in patients pre-
diabetes and obesity [46]. Taking the above mentioned into
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of diabetes to further lower central (aortic) blood pressure
may be highly beneficial.
Our study and relevance of our findings are limited in
the use of single methodolgy (myography) and the specifi-
city of the inhibitors.
Conclusions
In conclusion, we demonstrated that exenatide may lower
central (aortic) blood pressure by in a GLP-1R-dependent
manner mainly via H2S but also via NO, CO, O2
–• and
prostaglandins, and that this effect can be mediated via
the activion of PKA and PKG. Through the induction of
these mediators, exenatide also influences the activity of
potassium channels and the Na+/Ca2+ -exchanger.
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